<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630753</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1041</article-id><article-id pub-id-type="publisher-id">ofx163.1041</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dropulic</surname><given-names>Lesia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Kening</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Oestreich</surname><given-names>Makinna</given-names></name><degrees>B.A.</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Pietz</surname><given-names>Harlan</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Garabedian</surname><given-names>Doreen</given-names></name><degrees>BSN, RN</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Jegaskanda</surname><given-names>Sinthujan</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Dowdell</surname><given-names>Kennichi</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Hanh</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Laing</surname><given-names>Kerry</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Koelle</surname><given-names>David</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Azose</surname><given-names>Aaron</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Hunsberger</surname><given-names>Sally</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Lumbard</surname><given-names>Keith</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Aiying</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Lee-Jah</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Phogat</surname><given-names>Sanjay</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Jeffrey</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases</institution>, <addr-line>Bethesda, Maryland</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>University of Minnesota Medical School</institution>, <addr-line>Minneapolis, Minnesota</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Weill Cornell Medical College</institution>, <addr-line>New York City, NY</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>NIH</institution>, <addr-line>Bethesda, Maryland</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Peter Doherty Institute for Infection and Immunity</institution>, <addr-line>Melbourne</addr-line>, <country>Australia</country></aff><aff id="AF0006">
<label>6</label>
<institution>University of Washington Medicine</institution>, <addr-line>Seattle, Washington</addr-line></aff><aff id="AF0007">
<label>7</label>
<institution>Vanderbilt University Medical School</institution>, <addr-line>Nashville, Tennessee</addr-line></aff><aff id="AF0008">
<label>8</label>
<institution>Biostatistics Research Branch, NIAID</institution>, <addr-line>Bethesda, Maryland</addr-line></aff><aff id="AF0009">
<label>9</label>
<institution>sanofi pasteur</institution>, <addr-line>Swiftwater, Pennsylvania</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 152. Herpes Zoster Vaccine</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S415</fpage><lpage>S416</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1041.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>We conducted a phase 1, randomized, double-blind, placebo-controlled trial of a replication-defective HSV-2 vaccine, HSV529 (deleted for UL5 and UL29), in 60 healthy adults aged 18 to 40 years.</p></sec><sec id="s2"><title>Methods</title><p>Subjects were enrolled in groups of 20 from 3 serogroups: HSV1+ or &#x02028;-/HSV2+ (group 1), HSV1+/HSV2&#x02013; (group 2), and HSV1-/HSV2&#x02013; (group 3). At months 0, 1, and 6, 15 subjects in each group received HSV529 intramuscularly and 5 subjects received placebo. The primary endpoint was the frequency of solicited injection site and systemic reactions from day 0 to 7 after each vaccination and unsolicited adverse events up to 6 months after the last dose.</p></sec><sec id="s3"><title>Results</title><p>89% of vaccine recipients experienced a mild to moderate solicited injection site reaction vs. 47% of placebo recipients (P = 0.006, 95% CI 0.129, 0.676) that did not preclude additional doses. 64% of vaccine recipients experienced solicited systemic reactions vs. 53% of placebo recipients (P = 0.44, 95% CI -0.179, 0.402). Two serious adverse events occurred in 2 participants and were assessed as unrelated to HSV529 administration. Serum neutralizing antibody titers significantly increased from baseline after 3 doses of HSV529 compared with placebo in group 3 only (P &#x0003c; 0.001). This increase persisted up to 6 months after the third dose of vaccine (P &#x0003c; 0.001). Serum and vaginal antibodies to HSV2 glycoprotein D (gD) also significantly increased after 3 doses of vaccine in group 3 subjects (P &#x0003c; 0.001 and P = 0.012, respectively). The mean vaginal gD titer after 3 doses was about one-third of the mean serum gD titer. In addition, the vaccine induced significant levels of HSV2-specific antibody dependent cellular cytotoxicity (ADCC) after 3 doses in group 3 subjects compared with placebo (P &#x0003c; 0.001). Vaccine-induced CD4 T-cell responses were detected in 46%, 27%, and 36% of subjects in groups 1, 2, and 3, respectively, one month after the third dose of vaccine. CD8 T-cell responses were detected in 8%, 18%, and 14% of subjects in groups 1, 2, and 3, respectively, at the same time point.</p></sec><sec id="s4"><title>Conclusion</title><p>The HSV529 vaccine was safe, well-tolerated, and immunogenic, eliciting significant neutralizing, gD, and ADCC-mediating antibodies, and modest cellular immune responses in HSV seronegative individuals. NCT01915212</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>L. Dropulic</bold>, sanofi pasteur: Collaborator, Research support; <bold>K. Wang</bold>, sanofi pasteur: Collaborator, Research support; <bold>M. Oestreich</bold>, sanofi pasteur: Collaborator, Research support; <bold>H. Pietz</bold>, sanofi pasteur: Collaborator, Research support; <bold>D. Garabedian</bold>, sanofi pasteur: Collaborator, Research support; <bold>K. Dowdell</bold>, sanofi pasteur: Collaborator, Research support; <bold>H. Nguyen</bold>, sanofi pasteur: Collaborator, Research support; <bold>K. Laing</bold>, sanofi pasteur: Research Contractor, payment for conducting T cell assays; <bold>D. Koelle</bold>, sanofi pasteur: Research Contractor, payment for conducting T cell assays; <bold>A. Azose</bold>, sanofi pasteur: Research Contractor, Payment for conducting T cell assays; <bold>A. Chen</bold>, sanofi pasteur: Employee, Salary; <bold>L. J. Chang</bold>, sanofi pasteur: Employee, Salary; <bold>S. Phogat</bold>, sanofi pasteur: Employee, Salary</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>